AR128285A1 - Formulaciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos - Google Patents

Formulaciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos

Info

Publication number
AR128285A1
AR128285A1 ARP230100109A ARP230100109A AR128285A1 AR 128285 A1 AR128285 A1 AR 128285A1 AR P230100109 A ARP230100109 A AR P230100109A AR P230100109 A ARP230100109 A AR P230100109A AR 128285 A1 AR128285 A1 AR 128285A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloc1
alkoxy
group
membered heteroaryl
Prior art date
Application number
ARP230100109A
Other languages
English (en)
Inventor
Brian Lian
Geoffrey E Barker
Maureen Barnes
Kader Yagiz
Original Assignee
Viking Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viking Therapeutics Inc filed Critical Viking Therapeutics Inc
Publication of AR128285A1 publication Critical patent/AR128285A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulaciones de agonistas duales de los receptores de GIP / GLP-1 de molécula pequeña y usos de los mismos. Reivindicación 1: Una formulación farmacéutica a ser administrada a un sujeto en necesidad de la misma, caracterizada porque comprende: al menos 10% en peso de propilénglicol; y una dosis terapéuticamente eficaz de un compuesto que tiene la estructura de fórmula (1), o una sal farmacéuticamente aceptable del mismo, donde: R¹ se selecciona entre el grupo que consiste en -C(=O)(OZ¹), -P(=O)(X)(Y) y un heteroarilo de 5 - 10 miembros que contiene 1 - 2 heteroátomos seleccionados entre N, O y S opcionalmente sustituidos con 1 - 2 R⁷ seleccionados independientemente entre halógeno, C₁₋₆ alquilo, haloC₁₋₆ alquilo, haloC₁₋₆ alcoxi, -OR⁵, C₃₋₁₀ cicloalquilo, C₆₋₁₀ arilo, heteroarilo de 5 - 10 miembros y heterociclilo de 5 - 10 miembros; R² se selecciona entre el grupo que consiste en -C(=O)(OZ²), -P(=O)(X)(Y) y un heteroarilo de 5 - 10 miembros que contiene 1 - 2 heteroátomos seleccionados entre N, O y S opcionalmente sustituidos con 1 - 2 R⁷ seleccionados independientemente entre halógeno, C₁₋₆ alquilo, haloC₁₋₆ alquilo, haloC₁₋₆ alcoxi, -OR⁵, C₃₋₁₀ cicloalquilo, C₆₋₁₀ arilo, heteroarilo de 5 - 10 miembros y heterociclilo de 5 - 10 miembros; cada R⁷ se selecciona independientemente entre el grupo que consiste en halógeno, C₁₋₆ alquilo, haloC₁₋₆ alquilo, haloC₁₋₆ alcoxi, C₁₋₆ alcoxi, C₃₋₁₀ cicloalquilo, C₆₋₁₀ arilo, heteroarilo de 5 - 10 miembros y heterociclilo de 5 - 10 miembros; X e Y se seleccionan independientemente en cada caso entre el grupo que consiste en -OR⁴, NR⁵R⁶, C₁₋₆ alquilo y haloC₁₋₆ alquilo; cada R⁴ se selecciona independientemente entre el grupo que consiste en hidrógeno, C₁₋₆ alquilo, haloC₁₋₆ alquilo, C₆₋₁₀ ariloxi y C₆₋₁₀ arilalcoxi; cada R⁵ es independientemente hidrógeno o C₁₋₆ alquilo; cada R⁶ es independientemente hidrógeno o C₁₋₆ alquilo; y Z¹ y Z² se seleccionan independientemente en cada caso entre el grupo que consiste en hidrógeno, C₁₋₆ alquilo, haloC₁₋₆ alquilo, haloC₁₋₆ alcoxi, C₁₋₆ alcoxi, C₃₋₁₀ cicloalquilo y C₆₋₁₀ arilo, donde al menos uno de Z¹ y Z² no es hidrógeno.
ARP230100109A 2022-01-18 2023-01-18 Formulaciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos AR128285A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263300538P 2022-01-18 2022-01-18

Publications (1)

Publication Number Publication Date
AR128285A1 true AR128285A1 (es) 2024-04-10

Family

ID=87348890

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100109A AR128285A1 (es) 2022-01-18 2023-01-18 Formulaciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos

Country Status (5)

Country Link
KR (1) KR20240136386A (es)
AR (1) AR128285A1 (es)
AU (1) AU2023208627A1 (es)
TW (1) TW202339789A (es)
WO (1) WO2023141044A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020026372A2 (pt) * 2018-07-23 2021-03-23 Eli Lilly And Company métodos de uso de um coagonista de gip/glp1 para terapia
KR20240118914A (ko) * 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
WO2023141044A1 (en) 2023-07-27
KR20240136386A (ko) 2024-09-13
TW202339789A (zh) 2023-10-16
AU2023208627A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
AR119731A1 (es) Inhibidores del inflamasoma nlrp3
CL2021002883A1 (es) Moduladores de thr-ß y métodos de uso de estos
AR088919A2 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y uso
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR107927A1 (es) Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento
AR108906A1 (es) Heterociclos de biarilmetilo
ES2566973T9 (es) Uso de SNS-595 para tratar leucemia
JP2013541566A (ja) カルバゾール及びカルボリンの誘導体ならびにその調製及び治療法上の応用
ES2176288T3 (es) Compuestos de 2-(4-hidroxifenil)benzotiofeno, composiciones y procedimientos para alivir el sindrome postmenopausico.
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
AR054277A1 (es) Derivados de piperidin - 4 - il - amida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con la modulacion de receptores del subtipo 5 de la sst.
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR117206A1 (es) Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer
PE20220704A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos
AR118729A1 (es) Inhibidor selectivo de la jak1 quinasa
AR123757A1 (es) Inhibidores de las cinasas raf
AR127062A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos y hepáticos
AR115906A1 (es) Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas
AR127404A1 (es) Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
PE20181328A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR128285A1 (es) Formulaciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos
AR096728A1 (es) Derivados de estratrieno-tiazol terapéuticamente activos
AR125312A1 (es) Derivados heterocíclicos, composiciones farmacéuticas y su uso en el tratamiento o la mejora del cáncer
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento